NASDAQ:TVGN

Tevogen Bio Q3 2025 Earnings Results & Report

Tevogen Bio logo
$5.69 -0.53 (-8.52%)
Closing price 11/17/2026 03:53 PM Eastern
Extended Trading
$5.74 +0.04 (+0.79%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tevogen Bio beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$1.50 versus the -$3.04 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Tevogen Bio EPS Results

Actual EPS
-$1.50
Consensus EPS
-$3.04
Beat/Miss
Beat by +$1.54
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

Tevogen Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Tevogen Bio Q3 2025 Earnings FAQ

Tevogen Bio (NASDAQ:TVGN) reported earnings of -$1.50 per share for Q3 2025, beating the consensus estimate of -$3.04. The report was announced on Friday, November 14, 2025.

Tevogen Bio Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Tevogen Bio Holdings Rebrands as Tevogen Inc.
See More Tevogen Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email.

About Tevogen Bio

Tevogen Bio (NASDAQ:TVGN) is a clinical-stage biotechnology company developing cell-based immunotherapies. Its ExacTcell platform uses donor-derived, antigen-specific T cells designed to recognize and attack disease-associated targets, with the goal of making therapies available without creating a custom treatment for each patient.

The company’s lead investigational candidate, TVGN 489, is a T-cell therapy being developed for COVID-19. Tevogen is also pursuing potential applications of its platform in cancer and other diseases. Its candidates remain investigational and are not approved treatments.

Founded by physician and health economist Ryan Saadi, who serves as the company’s chief executive officer, Tevogen became a publicly traded company in 2024 through a merger with Semper Paratus Acquisition Corporation. The company is based in Warren, New Jersey.

View Tevogen Bio Profile